Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients  by Carreras, Enric et al.
Biology of Blood and Marrow Transplantation 13:1448-1454 (2007)
Q 2007 American Society for Blood and Marrow Transplantation
1083-8791/07/1312-0001$32.00/0
doi:10.1016/j.bbmt.2007.08.002Veno-Occlusive Disease of the Liver after High-Dose
Cytoreductive Therapy with Busulfan and Melphalan
for Autologous Blood Stem Cell Transplantation
in Multiple Myeloma Patients
Enric Carreras,1 Laura Rosi~nol,1 Maria Jose Terol,2 Adrian Alegre,3 Felipe de Arriba,4
Jose Garcıa-Lara~na,5 Jose Luis Bello,6 Raimundo Garcıa,7 Angel Leon,8 Rafael Martınez,9
M. Jesus Pe~narrubia,10 Concha Poderos,11 Paz Ribas,12 Josep Maria Ribera,13 Jesus San Miguel,14
Joan Blade,1 Juan Jose Lahuerta15 for the Spanish Myeloma Group/PETHEMA
Haematology Departments of 1Hospital Clınic, Barcelona, Spain; 2Hospital Clınico Universitario, Valencia, Spain;
3Hospital La Princesa, Madrid, Spain; 4Hospital Morales Meseguer, Murcia, Spain; 5Hospital Ramon y Cajal, Madrid,
Spain; 6Complejo Hospitalario Universitario, Santiago de Compostela, Spain; 7General Hospital, Castellon, Spain;
8General Hospital, Jerez de la Frontera, Spain; 9Hospital Universitario San Carlos, Madrid, Spain; 10Hospital
Universitario Rıo Ortega, Valladolid, Spain; 11Hospital Xeral-Cies, Pontevedra, Spain; 12Hospital Doctor Peset,
Valencia, Spain; 13Hospital Germans Trias i Pujol, Badalona, Spain; 14Hospital Universitario, Salamanca, Spain; and
15Hospital Universitario, 12 de Octubre, Madrid, Spain
Correspondence and reprint requests: Enric Carreras, MD, BMT Unit, Hematology Department, Hospital Clınic,
Villarroel 170, 08036 Barcelona, Spain; Tel: 34932275428; Fax: 34932275484 (e-mail: carreras@clinic.ub.es).
Received July 6, 2007; accepted August 6, 2007
ABSTRACT
Veno-occlusive disease of the liver (VOD) is a potentially severe complication of high-dose cytoreductive ther-
apy (HDT) used for stem cell transplantation (SCT). This complication is uncommon after HDT for autologous
SCT (ASCT) in patients with multiple myeloma (MM). The Spanish Myeloma Group/PETHEMA conducted
a study (MM2000) for patients with newly diagnosed MM consisting of induction with alternating VBMCP/
VBAD chemotherapy followed by intensification with busulfan/melphalan (Bu/MEL) with a second high-dose
therapy procedure in patients not achieving at least near-complete remission with the first procedure. After 2
years of the trial, a number of episodes resembling classical VOD but with a late onset were recognized. Con-
sequently, the protocol was modified, and Bu/MEL was replaced by melphalan 200 mg/m2 (MEL-200). Three
years later, after a total of 734 patients had undergone first autologous SCT, the incidence and characteristics
of VOD episodes were analyzed in the whole series. Nineteen cases of VOD (8%) were observed among the first
240 patients receiving Bu/MEL, whereas only 2 (0.4%) were observed among the 494 patients treated with
MEL-200 (P\ .0001). VOD manifestations in the Bu/MEL group appeared at a median of 29 days (range,
3–57 days) after ASCT. Mortality directly attributable to VOD was 2% in the Bu/MEL group and 0.2% in the
MEL-200 group (P 5 .026). This high incidence of severe VOD probably had a multifactorial origin (busulfan
followed by melphalan and previous use of BCNU). This observation should be kept in mind when designing
future trials for the treatment of MM.
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Veno-occlusive disease (VOD) of the liver, also
called sinusoidal obstruction syndrome, is a potentially
severe complication of high-dose cytoreductive ther-
apy (HDT) used for stem cell transplantation (SCT).1448This syndrome is characterized by hyperbilirubinemia,
hepatomegaly, and fluid accumulation resulting in
weight gain. The clinical course of VOD is usually
self-limited, but in some series the mortality rate has
been very high [1].
Veno-Occlusive Disease of the Liver after Cytoreductive Therapy for Multiple Myeloma 1449Several transplantation-related risk factors have
been associated with VOD, the most important being
the type of transplantation and the intensity of HDT.
Despite some initial reports of higher rates, the inci-
dence of VOD in patients receiving an autologous
SCT (ASCT) rarely exceeds 5%. However, in alloge-
neic SCT (allo-SCT), up to 54% of patients can
develop this complication [2]. A large prospective
survey on VOD performed by the European Group
for Blood and Marrow Transplantation found an
incidence of VOD of 3% in ASCT and 9% in allo-
SCT. The increased incidence of VOD in the alloge-
neic setting is likely linked to the alloreactivity and
hepatotoxicity of some drugs used in the procedure
[3].
Several studies have demonstrated a higher risk of
VOD in HDT in patients conditioned with regimens
including high-dose cyclophosphamide (Cy) associ-
ated with high-dose busulfan (Bu/Cy regimen), total
body radiation (TBI) (Cy/TBI regimen), or other
chemotherapeutic agents, such as the BCV regimen
(BCNU, Cy, etoposide). A high incidence of VOD
(28%) also has been observed in patients undergoing
ASCT receiving 3 alkylating agents (busulfan, melpha-
lan, and thiotepa) as a preparative regimen. Most
VODs associated with the use of multiple alkylating
agents had 2 special characteristics: a later onset (by
1-2 weeks with respect to VOD observed after regi-
mens including Cy) and, in 1/3 of cases, a double
peak of weight gain and hyperbilirubinemia associated
with an adverse prognosis.
In October 1999, the Spanish Myeloma Group/
PETHEMA started a new trial (MM2000) to evaluate
the role of a tandem SCT program with a second au-
tologous or reduced-intensity allo-SCT in patients
with newly diagnosed symptomatic multiple myeloma
(MM) not achieving complete remission (CR) or near-
CR with a first high-dose therapy procedure. Based on
the high antimyeloma efficacy demonstrated by the
alternating dexamethasone (VBMCP/VBAD) chemo-
therapy in our previous PETHEMA trial [4], this
treatment was selected as the initial induction regimen.
Additionally, based on the satisfactory results reported
by the Spanish Myeloma Group [5] and others [6,7],
the association of busulfan and melphalan (Bu/MEL)
was chosen as the HDT regimen for the first ASCT.
An interim analysis, performed 2 years after the
study was activated, demonstrated a high incidence
of VOD and unusually high transplantation-related
mortality (TRM), attributed mainly to this complica-
tion after the first ASCT. Because the main modifica-
tion with regard to previous trials of this cooperative
group had been the addition of busulfan to melphalan
in the preparative regimen, at this point the protocol
was modified by replacing Bu/MEL by melphalan
200 mg/m2 (MEL-200) in the intensification regimen.
Three years later, after 734 patients had received thefirst ASCT, the incidence of VOD was reassessed.
Here we report the results of this analysis.
PATIENTS AND METHODS
MM2000 Trial
All MM patients diagnosed in the 70 Spanish
institutions participating in the trial were centrally
registered. Patients under age 70 years with a perfor-
mance score status of 0–2 and untreated symptomatic
MM were eligible for the trial. The treatment sched-
ule consisted of 6 cycles of alternating vincristine,
BCNU, melphalan, cyclophosphamide, prednisone/
vincristine, BCNU, adriamycin, and VBMCP/
VBAD administered at 5- week intervals. Four weeks
after the fourth cycle of chemotherapy, peripheral
blood stem cells (PBSCs) were collected after mobili-
zation with 16-24 mg/kg/day of granulocyte colony-
stimulating factor (G-CSF) administered twice daily
for 5 days. Leukaphereses were performed following
each center’s institutional protocol, with a goal of
reaching a minimum of 4  106 CD341 cells/kg. Af-
ter PBSC collection, 2 additional cycles of VBMCP/
VBAD were administered to complete the 6 planned
cycles.
All patients with more than 2  106 CD341 cells/
kg cryopreserved underwent HDT and ASCT 1-2
months after the final cycle of chemotherapy. HDT
included oral busulfan 12 mg/kg on days 26 to 23
and melphalan 140 mg/m2 on day 22 (Bu/MEL
group). After the interim analysis performed in January
2002, when 240 patients had received the first ASCT,
the protocol was amended, and melphalan 200 mg/m2
was administered to the remaining 494 patients ana-
lyzed (MEL-200 group). The participating centers
did not modify their institutional protocols for VOD
prophylaxis as a consequence of the change in the
high-dose regimen.
Patient Selection for VODAnalysis
All consecutive patients included in MM2000 trial
since its starting date (October 1999) up to December
31, 2004, were included in the VOD analysis. In this
5-year period, 769 of the patients included had under-
gone at least the first HDT procedure. A total of 35 pa-
tients were excluded from the final analysis because
ASCT was performed with bone marrow (n 5 1),
bone marrow plus PBSCs (n 5 1), or manipulated
PBSCs (n 5 8) or used a conditioning regimen other
than the scheduled one (n5 25). Consequently, the fi-
nal analysis was focused on the 734 patients who re-
ceived the scheduled first ASCT with Bu/MEL or
MEL-200. Second autologous or allo-SCTs were not
included in this analysis. The main characteristics of
these patients at diagnosis and at the time of transplan-
tation, as well as their evolution after transplantation,
are summarized in Tables 1 and 2.
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Exhaustive information on all cases in which
a VOD was suspected after the first ASCT was re-
quested based on a specially designed questionnaire
sent to all reporting centers. The questionnaire
analyzed the following factors: patient- and transplan-
tation-related risk factors for VOD, use of any prophy-
lactic measures for VOD, clinical manifestations of
VOD and its timing, data on multiorgan failure, stud-
ies performed to confirm the diagnosis of VOD and to
evaluate its treatment and evolution. In addition, the
participating centers were requested to report any
change in their policy for VOD prophylaxis intro-
duced after the conditioning regimen was modified.
Diagnosis of VOD was established using both the
Seattle and Baltimore clinical criteria [2,8] but without
limiting the diagnosis to the first 21 days after PBSC
infusion. Briefly, the diagnosis of VOD was accepted
in those cases presenting during the first 60 days after
transplantation with 2 or more of the following (Seat-
tle criteria) or presenting with hyperbilirubinemia and
2 or more (Baltimore criteria) of the following: biliru-
binemia $ 2 mg/dL, weight gain $ 5%, painful hepa-
tomegaly, and ascites that could not be attributed to
other causes, such as sepsis, drug toxicity, or heart
failure.
The severity of VOD was classified using slightly
modified Seattle criteria [2]. When all signs and symp-
toms of VOD disappeared without treatment or with
fluid and sodium restriction and diuretic use as the
only measures, VOD was considered ‘‘mild.’’ Patients
requiring other therapeutic interventions were classi-
fied as having ‘‘moderate’’ VOD. Those cases not re-
solved by day 100 after ASCT, dying before this date
due to other causes with an active VOD, or in whom
death was directly attributable to VOD were consid-
ered ‘‘severe’’ VOD.
Table 1. Characteristics at diagnosis in the 739 patients undergoing HDT
Bu/MEL group MEL-200 group P
HDT performed 240 494
Period of inclusion 10/1999–2/2002 2/2002-12/31/04
Sex male/female, % 56/44 55/45
Age, years, median
(range)
58 (31-70) 59 (33-70) NS
DS stage, I/II/III, % 8/29/63 9/40/41 NS
DS stage, A/B, % 84/16 85/15 NS
Type of Ig, G/A/BJ/NS, % 53/24/21/2 53/27/18/2 NS
M component, g/dL* 3.9 3.5 NS
Albumin, g/dL* 3.7 3.6 NS
Hemoglobin, g/L* 10.4 11 NS
Calcium, mg/dL* 9.6 9.5 NS
B2-microglobuline, mg/dL* 3.1 3.05 NS
PCR* 0.9 0.8 NS
DS indicates Durie-Salmon; NS, not significant.
*Median values.Statistical Analysis
Descriptive statistical analysis was performed. The
statistical significance of multiple comparisons was
analyzed by a mean c2 test or Fisher’s exact test
when appropriate for categorical variables and by the
t test for continuous variables.
RESULTS
During the 2 trial periods (October 1999–January
2002, for Bu/MEL conditioning and February 2002–
December 31, 2004, for MEL-200 conditioning),
240 and 494 patients, respectively, underwent a first
ASCT and were included in the study.
Twenty-two possible cases of VODwere reported,
and after an exhaustive review, 21 of 734 evaluable pa-
tients (2.9%) were classified as having VOD. One case
reported as VOD was excluded from the final analysis
because it met only 1 of the clinical criteria for VOD.
Nineteen VOD cases (8%) were observed in the
first 240 patients (Bu/MEL group), compared with
only 2 (0.4%) in the 494 patients treated during
the second period (MEL-200 group) (P \ .0001)
(Table 3).
Only 2 patients in the Bu/MEL group had well-
established pretransplantation risk factors for VOD
(ie, increased transaminases because of hepatitis C
virus [HCV] infection and asymptomatic HCV infec-
tion, respectively). Thirteen patients (including both
Table 2. Characteristics at First HDT and Clinical Evolution
Group Bu/MEL MEL-200 P
HDT performed 240 494
Status before HDT
Complete response 16 12 NS
EF-complete response 14 14
Partial response 54 58
Minor response 8 8
Stabilization 3 4
Progression 5 4
M component, g/dL* 0.7 0.7 NS
Interval diagnosis-HDT, months* 9.1 9.3 NS
ECOG 2-3 at HDT, %* 7 6 NS
PBSC CD341,  10e6/kg* 2.7 2.6 NS
.500 neutrophils, day*/** 11/11 11/12 NS
.20,000 platelets, day*/** 12/14 12/14 NS
Hospitalization, days (± 95% CI)* 19 (17-21) 17 (15-19) NS
Maximum response, %†
Complete response 37 37 NS
EF - complete response 13 20
Partial response 22 24
Minor response 7 5
Stabilization 11 8
Progression 2 3
TRM, % 8 3 .001
TRMindicates transplantation-relatedmortality;EF, electrophoresis.
*Median; **mean.
†Excluding 3% of cases not valuable because of short follow-up.
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phylactic measures to prevent this complication,
whereas the remaining 8 received sodium heparin
(n 5 5), low molecular weight heparin (n 5 2), or ur-
sodeoxycholic acid (n 5 1). In any case, prophylactic
measures were used because of the presence of risk
factors for VOD, but because of institutional proto-
cols, none of the groups reporting patients with
VOD modified their policy of VOD prophylaxis.
Eleven patients presented with 4 clinical criteria
for VOD, and 9 patients presented with 3 of these cri-
teria. One patient presented with only 2 clinical VOD
criteria, but his evolution was consistent with the diag-
nosis of severe VOD, including multiorgan failure.
Consequently, 21 patients fulfilled the Seattle clinical
criteria, and 20 patients (95%) fulfilled the Baltimore
criteria.
Clinical manifestations of VOD appeared after 9
and 13 days in the 2 patients in MEL-200 group and
after a median of 29 days (range, 3–57 days) in the
Bu/MEL group. In 14 of 19 patients in the Bu/MEL
group (74%), VOD manifestations appeared beyond
day 21 after ASCT. Eleven (52%) patients in Bu/
MEL group developed symptoms of VOD a mean of
15 days (range, 8-43 days) after hospital discharge,
and 10 of these patients required readmission. The de-
scribed biphasic evolution of VODwas not observed in
any of our cases.
All patients had hyperbilirubinemia (median, 4
mg/dL; range, 2–48 mg/dL), 17 had weight gain (me-
dian, 7%; range, 5%–20%), 19 developed hepatomeg-
aly (10 with pain), and 15 had ascites (demonstrated by
ultrasound studies in 1 case). Seven patients (33%) de-
Table 3. Characteristics of VOD
Group Bu/MEL MEL-200
VOD cases/patients included (%) 19/240 (8) 2/494 (0.4)†
Diagnosis, days after SCT 29 (3–57)* 9 and 13
VOD cases after day 121 (%) 14 (74) –
Outpatient at VOD diagnosis 11 0
Days after discharge* 15 (8–43) –
Patients with 2/3/4 clinical criteria 1/7/11 0/2/0
Baltimore criteria (%) 18 (94) 2 (100)
Multiorgan failure (%) 6 (31.5) 1 (50)
Evolution of VOD cases
Alive and asymptomatic by
day 100 (%)
11 (58) 0
Time to VOD resolution, days 17 (5-52) –
Alive by day 1 100 with VOD 2 –
Patients dying before day 1100 5 2
From other causes with VOD – 1
From VOD (%) 5 (26) 1 (50)
Time to death from VOD, days 25 (7-42)* 6
Mild/moderate/severe VOD (%) 42/21/39 0/0/100
Mortality directly attributable to VOD 2% 0.2%‡
*Median (range).
†P\ .0001.
‡P 5 .026.veloped multiorgan failure (7 renal, 7 respiratory, 6
neurologic, and 1 cardiac).
Two patients were evaluated by means of hemody-
namic studies plus transvenous liver biopsies, and 2
patients were evaluated by transparietal liver biopsy.
In all of these patients, the diagnosis of VOD was con-
firmed histologically. Fourteen patients (67%) were
evaluated by ultrasound studies as well, and all demon-
strated findings consistent with VOD. All but 1 patient
received 1 or more of the following treatments: hydro-
saline restriction with or without diuretics (n5 20), so-
dium heparin (n 5 2), low molecular weight heparin
(n 5 4), ursodeoxycholic acid (n 5 4), rtPA (n 5 1),
ATIII (n 5 1), and defibrotide (n 5 5). In 11 patients
(52%), VOD resolved completely after a median of
17 days (range, 5-52 days). Two patients were alive
with persistent clinical manifestations of portal hyper-
tension after more than 4 years of follow-up. Six pa-
tients (28%)—5 from the Bu/MEL group and 1 from
the MEL-200 group—died from VOD after a median
of 25 days from VOD diagnosis (range, 7-42 days).
One additional patient in MEL-200 group died from
an invasive candidiasis with an active VOD. Conse-
quently, VOD could be classified as mild in 8 cases
(38%), moderate in 4 cases (19%), and severe in 9 cases
(43%). Mortality directly attributable to VODwas 2%
in the Bu/MEL group and 0.2% in the MEL-200
group (P 5 .026).
DISCUSSION
In an attempt to further improve our results with
ASCT in MM patients, we designed the MM2000
trial using our successful induction regimen, alternat-
ing VBMCP/VBAD followed by Bu/MEL as the
conditioning regimen. This decision was based on
the good results reported by a Spanish group using
VBMCP/VBAD chemotherapy [6] and by a previous
PETHEMA analysis comparing 3 different HDTs
that showed a trend for better results with Bu/MEL
[5].
Surprisingly, during the first 2 years of the study,
some investigators recognized a number of episodes
reassembling classical VOD but developing late after
transplantation, in some cases after hospital discharge.
Based on recently published articles describing a high
incidence of late-onset VOD in older patients receiv-
ing busulfan-containing regimens [9] or 3 alkylating
agents (busulfan, melphalan, and thiotepa) [10], we de-
cided to perform an interim analysis. This analysis
found an incidence of VOD of 8% and an incidence
of TRM directly attributable to VOD of 2%. Conse-
quently, we decided to replace the Bu/MEL regimen
by the more conventional MEL-200 regimen without
modifying any prophylaxis for VOD, and to closely
monitor the incidence of VOD. After this modifica-
tion, among the almost 500 additional ASCTs
1452 E. Carreras et al.performed, the incidence of VOD was 0.4%, and no
additional cases of late-onset VOD were observed.
Because the only difference between Bu/MEL and
MEL-200 groups was the conditioning regimen, it was
evident that the inclusion of busulfan was the cause of
our atypical VOD cases. Oral busulfan has an erratic
gastrointestinal absorption, and its metabolism and
elimination can be modified by many factors. This
fact explains the great interpatient variability of oral
busulfan plasma levels. Relevant factors influencing
busulfan plasma levels include patient age [11], some
genetic polymorphisms (eg, a GSTM1-null genotype)
[12], and interactions with other drugs (eg, estrogen
and other chemotherapy agents used in SCT) [13],
among others. Several investigators have identified
a significant relationship between the average steady-
state concentration and area under the curve of busul-
fan and outcome in SCT. In these studies, high serum
busulfan levels were correlated with a significant risk of
seizures and VOD, and low levels were correlated with
an increased risk of relapse and graft failure [14-17].
VOD occurs with a frequency of approximately 20%
with amortality of 6%–12% in patients receiving a pre-
parative regimen containing 16 mg/kg of oral busul-
fan. For this reason, some authors recommend the
therapeutic monitoring of busulfan dosage in patients
receiving the Bu/Cy regimen [14,18] and in those re-
ceiving Bu/MEL [19]. Despite this fact, other studies
have not observed a significant correlation between
steady-state busulfan concentrations and the develop-
ment of VOD [17,20].
Busulfan produces a reduction in intracellular glu-
tathione (GSH) [21,22] that influences metabolism of
other hepatotoxic drugs (especially Cy metabolites)
and these toxic metabolites are directly responsible
of sinusoidal cell toxicity [23,24]. This nondirect toxic-
ity is also suggested by the observation that lower bu-
sulfan doses (12 mg/kg) produce a higher incidence of
hepatic toxicity when associated with drugs that use
the same enzymatic system metabolism pathway
[10,13]. However, the information on busulfan toxicity
when used at 12 mg/kg associated with other drugs is
scarce [25].
Cytoplasmic metabolism of melphalan occurs
mainly through GSH enzymatic systems. High levels
of GSH have been associated with leukemic cell resis-
tance to melphalan, and low levels have been associ-
ated with increased sensibility and systemic toxicity
[26]. Melphalan at intravenous doses of 140 mg/m2
can produce transient elevations of serum transami-
nases and bilirubin in patients withMM [10]However,
when melphalan is used to treat other diseases (eg,
breast cancer, ovarian cancer, other hematologic ma-
lignancies) at higher doses (140–240 mg/m2) [27-30],
to treat MM in tandem courses [31,32], or in associa-
tion with BCNU, etoposide, and cytarabine [33-35],
minimal liver toxicity is observed.A possible explanation of the increased incidence
of VOD in series using melphalan associated with bu-
sulfan with or without other alkylating agents could be
that the toxicity of melphalan is enhanced when
administered after busulfan. In this situation, GSH de-
pletion from busulfan can alter melphalan clearance
and make GSH-depleted cells more sensitive to the ef-
fect of melphalan [36,37]. This mechanism could ex-
plain the better response rate observed in MM
patients treated with Bu/MEL [38], as well as the find-
ing in one study that 2 of 24 patients receiving 16mg/kg
of busulfan and 140 mg/m2 of melphalan to treat lym-
phoma developed VOD [39]. Moreover, in another
study the addition of 135mg/m2 of melphalan to a reg-
imen containing 16 mg/kg of busulfan and 120 mg/kg
of Cy resulted in an unacceptably high incidence of
severe VOD [40]. In line with these findings, VOD
was observed in 70 of 253 consecutive patients (28%)
undergoing ASCT receiving 100 mg/m2 of melphalan
with 12 mg/kg of busulfan and 500 mg/m2 of thiotepa
[10].
Despite all of these possible explanations for our
findings, 1 question remains: Why has this high inci-
dence of VOD in patients receiving Bu/MEL not
been reported previously [5-7]? The simplest explana-
tion for this could be that VOD has been underdiag-
nosed, because of the small number of patients
included in most series and VOD’s atypical presenta-
tion. In fact, a review of the data from previous PE-
THEMA trials revealed that in the 472 MM patients
undergoing ASCT with 4 different conditioning regi-
mens, the 3 patients who died from VOD had received
Bu/MEL (3 of 186 cases [1.6%]) [38]. In addition, we
can hypothesize about another possible cause of the
high incidence of VOD in the present series. All of
these patients received BCNU (180 mg/m2) with the
alternating VBMCP/VBAD cycles administered be-
fore ASCT. BCNU itself is a potent inactivator of
GSH reductase, an enzyme that reduces glutathione
disulfide to GSH. In addition, the BCNU electro-
philic toxic decomposition product 2-chloroethyl iso-
cyanate is also scavenged by GSH by forming
a glutathione conjugate. Both mechanisms notably re-
duce GSH activity, decreasing conjugation and in-
creasing the toxicity of agents administered
subsequently [41,42]. In addition, experimental stud-
ies have shown that the administration of glutathione
monoethyl ester selectively protects the liver from
high doses of BCNU and Cy [43]. Consequently, it
is possible that our patients underwent HDT with de-
creased GSH activity because of previous BCNU ad-
ministration. Subsequent administration of high
doses of busulfan increases this enzymatic reduction,
favoring both busulfan and melphalan toxicity. The
low incidence of VOD among patients receiving Bu/
MEL after chemotherapeutic regimens that do not
contain BCNU in patients with MM (DAV [7],
Veno-Occlusive Disease of the Liver after Cytoreductive Therapy for Multiple Myeloma 1453VAD [44,45], VAMP [46]) or with other diseases [47-
50] supports this hypothesis.
In conclusion, the high incidence of VOD ob-
served in our series can be the result of a multifactorial
toxicity (busulfan followed by melphalan and the pre-
vious use of BCNU). This observation can be crucial
for MM patients, because the follow-up of patients in-
cluded in PETHEMA trials (MM2000 and earlier)
confirms preliminary observations indicating a better
response rate for those receiving Bu/MEL [38] (last
follow-up not shown). Knowledge of the precise
pathogenesis of VOD in Bu/MEL would allow the
adoption of preventive measures (eg, glutathione sup-
plements [51,52], prophylactic defibrotide administra-
tion [53], targeted oral busulfan [19], or intravenous
busulfan [54]), which could help prevent the liver
toxicity associated with Bu/MEL in MM patients.
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